{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T03:03:31Z","timestamp":1791169411236,"version":"4.1.0"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2013,7,14]],"date-time":"2013-07-14T00:00:00Z","timestamp":1373760000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Apoptosis"],"published-print":{"date-parts":[[2013,11]]},"DOI":"10.1007\/s10495-013-0882-y","type":"journal-article","created":{"date-parts":[[2013,7,13]],"date-time":"2013-07-13T07:13:05Z","timestamp":1373699585000},"page":"1437-1446","source":"Crossref","is-referenced-by-count":30,"title":["FTY720 induces apoptosis of chronic myelogenous leukemia cells via dual activation of BIM and BID and overcomes various types of resistance to tyrosine kinase inhibitors"],"prefix":"10.1007","volume":"18","author":[{"given":"Miki","family":"Kiyota","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junya","family":"Kuroda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mio","family":"Yamamoto-Sugitani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuji","family":"Shimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryuko","family":"Nakayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hisao","family":"Nagoshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinsuke","family":"Mizutani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiaki","family":"Chinen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nana","family":"Sasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natsumi","family":"Sakamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsutomu","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yosuke","family":"Matsumoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeo","family":"Horiike","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masafumi","family":"Taniwaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,7,14]]},"reference":[{"key":"882_CR1","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1056\/NEJMoa022457","volume":"348","author":"SG O\u2019Brien","year":"2003","unstructured":"O\u2019Brien SG, Guilhot F, Larson RA et al (2003) Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 348:994\u20131004","journal-title":"N Engl J Med"},{"key":"882_CR2","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1056\/NEJMoa1002315","volume":"362","author":"H Kantarjian","year":"2010","unstructured":"Kantarjian H, Shah NP, Hochhaus A et al (2010) Dasatinib versus imatinib in newly diagnosed chronicphase chronic myeloid leukemia. N Engl J Med 362:2260\u20132270","journal-title":"N Engl J Med"},{"key":"882_CR3","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1056\/NEJMoa0912614","volume":"362","author":"G Saglio","year":"2010","unstructured":"Saglio G, Kim DW, Issaragrisil S et al (2010) Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med 362:2251\u20132259","journal-title":"N Engl J Med"},{"key":"882_CR4","doi-asserted-by":"crossref","first-page":"69","DOI":"10.2174\/156800913804486638","volume":"13","author":"J Kuroda","year":"2013","unstructured":"Kuroda J, Shimura Y, Yamamoto-Sugitani M, Sasaki N, Taniwaki M (2013) Multifaceted mechanisms for cell survival and drug targeting in chronic myelogenous leukemia. Curr Cancer Drug Targ 13:69\u201379","journal-title":"Curr Cancer Drug Targ"},{"key":"882_CR5","doi-asserted-by":"crossref","first-page":"14907","DOI":"10.1073\/pnas.0606176103","volume":"103","author":"J Kuroda","year":"2006","unstructured":"Kuroda J, Puthalakath H, Cragg MS et al (2006) Bim and Bad mediate imatinib-induced killing of Bcr\/Abl+ leukemic cells, and resistance due to their loss is overcome by a BH3 mimetic. Proc Natl Acad Sci USA 103:14907\u201314912","journal-title":"Proc Natl Acad Sci USA"},{"key":"882_CR6","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1038\/sj.cdd.4402168","volume":"14","author":"J Kuroda","year":"2007","unstructured":"Kuroda J, Kimura S, Strasser A et al (2007) Apoptosis-based dual molecular targeting by INNO-406, a second-generation Bcr-Abl inhibitor, and ABT-737, an inhibitor of antiapoptotic Bcl-2 proteins, against Bcr-Abl-positive leukemia. Cell Death Differ 14:1667\u20131677","journal-title":"Cell Death Differ"},{"key":"882_CR7","doi-asserted-by":"crossref","first-page":"19466","DOI":"10.1073\/pnas.0609239103","volume":"103","author":"BJ Skaggs","year":"2006","unstructured":"Skaggs BJ, Gorre ME, Ryvkin A et al (2006) Phosphorylation of the ATP-binding loop directs oncogenicity of drug-resistant BCR-ABL mutants. Proc Natl Acad Sci USA 103:19466\u201319471","journal-title":"Proc Natl Acad Sci USA"},{"key":"882_CR8","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1126\/science.1062538","volume":"293","author":"ME Gorre","year":"2001","unstructured":"Gorre ME, Mohammed M, Ellwood K et al (2001) Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 293:876\u2013880","journal-title":"Science"},{"key":"882_CR9","doi-asserted-by":"crossref","first-page":"17468","DOI":"10.1073\/pnas.1111138108","volume":"108","author":"M Yamamoto-Sugitani","year":"2011","unstructured":"Yamamoto-Sugitani M, Kuroda J, Ashihara E et al (2011) Galectin-3 (Gal-3) induced by leukemia microenvironment promotes drug resistance and bone marrow lodgment in chronic myelogenous leukemia. Proc Natl Acad Sci USA 108:17468\u201317473","journal-title":"Proc Natl Acad Sci USA"},{"key":"882_CR10","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1038\/cdd.2008.107","volume":"15","author":"Y Kamitsuji","year":"2008","unstructured":"Kamitsuji Y, Kuroda J, Kimura S et al (2008) The Bcr-Abl kinase inhibitor INNO-406 induces autophagy and different modes of cell death execution in Bcr-Abl-positive leukemias. Cell Death Differ 15:1712\u20131722","journal-title":"Cell Death Differ"},{"key":"882_CR11","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1172\/JCI35660","volume":"119","author":"C Bellodi","year":"2009","unstructured":"Bellodi C, Lidonnici MR, Hamilton A et al (2009) Targeting autophagy potentiates tyrosine kinase inhibitor-induced cell death in Philadelphia chromosome-positive cells, including primary CML stem cells. J Clin Invest 119:1109\u20131123","journal-title":"J Clin Invest"},{"key":"882_CR12","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1002\/ajh.21914","volume":"86","author":"LC Crowley","year":"2011","unstructured":"Crowley LC, Elzinga BM, O\u2019Sullivan GC, McKenna SL (2011) Autophagy induction by Bcr-Abl-expressing cells facilitates their recovery from a targeted or nontargeted treatment. Am J Hematol 86:38\u201347","journal-title":"Am J Hematol"},{"key":"882_CR13","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1042\/BST0351347","volume":"35","author":"HG J\u00f8rgensen","year":"2007","unstructured":"J\u00f8rgensen HG, Holyoake TL (2007) Characterization of cancer stem cells in chronic myeloid leukaemia. Biochem Soc Trans 35:1347\u20131351","journal-title":"Biochem Soc Trans"},{"key":"882_CR14","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1056\/NEJMoa040258","volume":"351","author":"CH Jamieson","year":"2004","unstructured":"Jamieson CH, Ailles LE, Dylla SJ et al (2004) Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML. N Engl J Med 351:657\u2013667","journal-title":"N Engl J Med"},{"key":"882_CR15","doi-asserted-by":"crossref","first-page":"5191","DOI":"10.1182\/blood-2008-08-176016","volume":"114","author":"RM Lemoli","year":"2009","unstructured":"Lemoli RM, Salvestrini V, Bianchi E et al (2009) Molecular and functional analysis of the stem cell compartment of chronic myelogenous leukemia reveals the presence of a CD34- cell population with intrinsic resistance to imatinib. Blood 114:5191\u20135200","journal-title":"Blood"},{"key":"882_CR16","doi-asserted-by":"crossref","first-page":"4532","DOI":"10.1182\/blood-2005-07-2947","volume":"107","author":"M Copland","year":"2006","unstructured":"Copland M, Hamilton A, Elrick LJ et al (2006) Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction. Blood 107:4532\u20134539","journal-title":"Blood"},{"key":"882_CR17","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1172\/JCI35721","volume":"121","author":"AS Corbin","year":"2011","unstructured":"Corbin AS, Agarwal A, Loriaux M, Cortes J, Deininger MW, Druker BJ (2011) Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity. J Clin Invest 121:396\u2013409","journal-title":"J Clin Invest"},{"key":"882_CR18","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1038\/cdd.2010.6","volume":"17","author":"M Takeuchi","year":"2010","unstructured":"Takeuchi M, Kimura S, Kuroda J et al (2010) Glyoxalase-I is a novel target against Bcr-Abl+ leukemic cells acquiring stem-like characteristics in a hypoxic environment. Cell Death Differ 17:1211\u20131220","journal-title":"Cell Death Differ"},{"key":"882_CR19","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.ccr.2011.05.007","volume":"19","author":"T Schmidt","year":"2011","unstructured":"Schmidt T, Kharabi Masouleh B, Loges S et al (2011) Loss or inhibition of stromal-derived PlGF prolongs survival of mice with imatinib-resistant Bcr-Abl1(+) leukemia. Cancer Cell 19:740\u2013753","journal-title":"Cancer Cell"},{"key":"882_CR20","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1038\/sj.leu.2402179","volume":"15","author":"JS Damiano","year":"2001","unstructured":"Damiano JS, Hazlehurst LA, Dalton WS (2001) Cell adhesion-mediated drug resistance (CAM-DR) protects the K562 chronic myelogenous leukemia cell line from apoptosis induced by BCR\/ABL inhibition, cytotoxic drugs, and gamma-irradiation. Leukemia 15:1232\u20131239","journal-title":"Leukemia"},{"key":"882_CR21","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1158\/1535-7163.MCT-07-0042","volume":"7","author":"L Jin","year":"2008","unstructured":"Jin L, Tabe Y, Konoplev S et al (2008) CXCR4 up-regulation by imatinib induces chronic myelogenous leukemia (CML) cell migration to bone marrow stroma and promotes survival of quiescent CML cells. Mol Cancer Ther 7:48\u201358","journal-title":"Mol Cancer Ther"},{"key":"882_CR22","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1182\/blood-2006-08-040022","volume":"109","author":"Y Wang","year":"2007","unstructured":"Wang Y, Cai D, Brendel C et al (2007) Adaptive secretion of granulocyte-macrophage colony-stimulating factor (GM-CSF) mediates imatinib and nilotinib resistance in BCR\/ABL+ progenitors via JAK-2\/STAT-5 pathway activation. Blood 109:2147\u20132155","journal-title":"Blood"},{"key":"882_CR23","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1038\/nm.2713","volume":"18","author":"KP Ng","year":"2012","unstructured":"Ng KP, Hillmer AM, Chuah CT et al (2012) A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer. Nat Med 18:521\u2013528","journal-title":"Nat Med"},{"key":"882_CR24","doi-asserted-by":"crossref","first-page":"6660","DOI":"10.1182\/blood-2010-08-304477","volume":"117","author":"CM Lucas","year":"2011","unstructured":"Lucas CM, Harris RJ, Giannoudis A, Copland M, Slupsky JR, Clark RE (2011) Cancerous inhibitor of PP2A (CIP2A) at diagnosis of chronic myeloid leukemia is a critical determinant of disease progression. Blood 117:6660\u20136668","journal-title":"Blood"},{"key":"882_CR25","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/S1470-2045(10)70233-3","volume":"11","author":"FX Mahon","year":"2010","unstructured":"Mahon FX, R\u00e9a D, Guilhot J et al (2010) Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2\u00a0years: the prospective, multicentre stop imatinib (STIM) trial. Lancet Oncol 11:1029\u20131035","journal-title":"Lancet Oncol"},{"key":"882_CR26","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1038\/leu.2010.185","volume":"24","author":"DM Ross","year":"2010","unstructured":"Ross DM, Branford S, Seymour JF et al (2010) Patients with chronic myeloid leukemia who maintain a complete molecular response after stopping imatinib treatment have evidence of persistent leukemia by DNA PCR. Leukemia 24:1719\u20131724","journal-title":"Leukemia"},{"key":"882_CR27","doi-asserted-by":"crossref","first-page":"37","DOI":"10.2298\/VSP1201037S","volume":"69","author":"D Stamatovi\u0107","year":"2012","unstructured":"Stamatovi\u0107 D, Balint B, Tuki\u0107 L et al (2012) Allogeneic stem cell transplant for chronic myeloid leukemia as a still promising option in the era of the new target therapy. Vojnosanit Pregl 69:37\u201342","journal-title":"Vojnosanit Pregl"},{"key":"882_CR28","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1042\/0264-6021:3530417","volume":"353","author":"V Janssens","year":"2001","unstructured":"Janssens V, Goris J (2001) Protein phosphatase 2A: a highly regulated family of serine\/threonine phosphatases implicated in cell growth and signalling. Biochem J 353:417\u2013439","journal-title":"Biochem J"},{"key":"882_CR29","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.gde.2004.12.004","volume":"15","author":"V Janssens","year":"2005","unstructured":"Janssens V, Goris J, Van Hoof C (2005) PP2A: the expected tumor suppressor. Curr Opin Genet Dev 15:34\u201341","journal-title":"Curr Opin Genet Dev"},{"key":"882_CR30","first-page":"1410","volume":"62","author":"H Azuma","year":"2002","unstructured":"Azuma H, Takahara S, Ichimaru N et al (2002) Marked Prevention of Tumor Growth and Metastasis by a Novel Immunosuppressive Agent, FTY720, in Mouse Breast Cancer Models. Cancer Res 62:1410\u20131419","journal-title":"Cancer Res"},{"key":"882_CR31","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1038\/sj.onc.1203389","volume":"19","author":"GA Calin","year":"2000","unstructured":"Calin GA, di Iasio MG, Caprini E et al (2000) Low frequency of alterations of the alpha (PPP2R1A) and beta (PPP2R1B) isoforms of the subunit A of the serine-threonine phosphatase 2A in human neoplasms. Oncogene 19:1191\u20131195","journal-title":"Oncogene"},{"key":"882_CR32","first-page":"1263","volume":"23","author":"K Suzuki","year":"2003","unstructured":"Suzuki K, Takahashi K (2003) Reduced expression of the regulatory A subunit of serine\/threonine protein phosphatase 2A in human breast cancer MCF-7 cells. Int J Oncol 23:1263\u20131268","journal-title":"Int J Oncol"},{"key":"882_CR33","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1136\/gut.47.2.268","volume":"47","author":"Y Takagi","year":"2000","unstructured":"Takagi Y, Futamura M, Yamaguchi K, Aoki S, Takahashi T, Saji S (2000) Alterations of the PPP2R1B gene located at 11q23 in human colorectal cancers. Gut 47:268\u2013271","journal-title":"Gut"},{"key":"882_CR34","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.ccr.2005.10.015","volume":"8","author":"P Neviani","year":"2005","unstructured":"Neviani P, Santhanam R, Trotta R et al (2005) The tumor suppressor PP2A is functionally inactivated in blast crisis CML through the inhibitory activity of the BCR\/ABL-regulated SET protein. Cancer Cell 8:355\u2013368","journal-title":"Cancer Cell"},{"key":"882_CR35","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1056\/NEJMoa052643","volume":"355","author":"L Kappos","year":"2006","unstructured":"Kappos L, Antel J, Comi G et al (2006) Oral fingolimod (FTY720) for relapsing multiple sclerosis. N Engl J Med 355:1124\u20131140","journal-title":"N Engl J Med"},{"key":"882_CR36","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1056\/NEJMoa0907839","volume":"362","author":"JA Cohen","year":"2010","unstructured":"Cohen JA, Barkhof F, Comi G et al (2010) Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 362:402\u2013415","journal-title":"N Engl J Med"},{"key":"882_CR37","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/S1474-4422(12)70056-X","volume":"11","author":"V Devonshire","year":"2012","unstructured":"Devonshire V, Havrdova E, Radue EW et al (2012) Relapse and disability outcomes in patients with multiple sclerosis treated with fingolimod: subgroup analyses of the double-blind, randomised, placebo-controlled FREEDOMS study. Lancet Neurol 11:420\u2013428","journal-title":"Lancet Neurol"},{"key":"882_CR38","doi-asserted-by":"crossref","first-page":"21453","DOI":"10.1074\/jbc.C200176200","volume":"277","author":"V Brinkmann","year":"2002","unstructured":"Brinkmann V, Davis MD, Heise CE et al (2002) The immune modulator FTY720 targets sphingosine 1-phosphate receptors. J Biol Chem 277:21453\u201321457","journal-title":"J Biol Chem"},{"key":"882_CR39","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1126\/science.1070238","volume":"296","author":"S Mandala","year":"2002","unstructured":"Mandala S, Hajdu R, Bergstrom J et al (2002) Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonists. Science 296:346\u2013349","journal-title":"Science"},{"key":"882_CR40","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1038\/nature02284","volume":"427","author":"M Matloubian","year":"2004","unstructured":"Matloubian M, Lo CG, Cinamon G et al (2004) Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1. Nature 427:355\u2013360","journal-title":"Nature"},{"key":"882_CR41","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1172\/JCI31095","volume":"117","author":"P Neviani","year":"2007","unstructured":"Neviani P, Santhanam R, Oaks JJ et al (2007) FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia. J Clin Invest 117:2408\u20132421","journal-title":"J Clin Invest"},{"key":"882_CR42","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.1182\/blood-2011-01-331447","volume":"118","author":"A Liao","year":"2011","unstructured":"Liao A, Broeg K, Fox T et al (2011) Therapeutic efficacy of FTY720 in a rat model of NK-cell leukemia. Blood 118:2793\u20132800","journal-title":"Blood"},{"key":"882_CR43","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1182\/blood-2006-10-053884","volume":"111","author":"Q Liu","year":"2008","unstructured":"Liu Q, Zhao X, Frissora F et al (2008) FTY720 demonstrates promising preclinical activity for chronic lymphocytic leukemia and lymphoblastic leukemia\/lymphoma. Blood 111:275\u2013284","journal-title":"Blood"},{"key":"882_CR44","doi-asserted-by":"crossref","first-page":"3182","DOI":"10.1158\/1078-0432.CCR-09-2484","volume":"16","author":"Q Liu","year":"2010","unstructured":"Liu Q, Alinari L, Chen CS et al (2010) FTY720 shows promising in vitro and in vivo preclinical activity by downmodulating Cyclin D1 and phospho-Akt in mantle cell lymphoma. Clin Cancer Res 16:3182\u20133192","journal-title":"Clin Cancer Res"},{"key":"882_CR45","doi-asserted-by":"crossref","first-page":"5438","DOI":"10.1158\/0008-5472.CAN-09-2544","volume":"70","author":"KG Roberts","year":"2010","unstructured":"Roberts KG, Smith AM, McDougall F et al (2010) Essential requirement for PP2A inhibition by the oncogenic receptor c-KIT suggests PP2A reactivation as a strategy to treat c-KIT+ cancers. Cancer Res 70:5438\u20135447","journal-title":"Cancer Res"},{"key":"882_CR46","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1046\/j.1365-2567.1997.d01-2281.x","volume":"91","author":"T Shinomiya","year":"1997","unstructured":"Shinomiya T, Li XK, Amemiya H, Suzuki S (1997) An immunosuppressive agent, FTY720, increases intracellular concentration of calcium ion and induces apoptosis in HL-60. Immunology 91:594\u2013600","journal-title":"Immunology"},{"key":"882_CR47","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1002\/ijc.10178","volume":"98","author":"S Permpongkosol","year":"2002","unstructured":"Permpongkosol S, Wang JD, Takahara S et al (2002) Anticarcinogenic effect of FTY720 in human prostate carcinoma DU145 cells: modulation of mitogenic signaling, FAK, cell-cycle entry and apoptosis. Int J Cancer 98:167\u2013172","journal-title":"Int J Cancer"},{"key":"882_CR48","doi-asserted-by":"crossref","first-page":"3078","DOI":"10.1016\/S0041-1345(01)02312-0","volume":"33","author":"V Brinkmann","year":"2001","unstructured":"Brinkmann V, Wilt C, Kristofic C et al (2001) FTY720: dissection of membrane receptor-operated, stereospecific effects on cell migration from receptor-independent antiproliferative and apoptotic effects. Transplant Proc 33:3078\u20133080","journal-title":"Transplant Proc"},{"key":"882_CR49","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1038\/nrc1411","volume":"4","author":"B Ogretmen","year":"2004","unstructured":"Ogretmen B, Hannun YA (2004) Biologically active sphingolipids in cancer pathogenesis and treatment. Nat Rev Cancer 4:604\u2013616","journal-title":"Nat Rev Cancer"},{"key":"882_CR50","doi-asserted-by":"crossref","first-page":"14788","DOI":"10.1073\/pnas.0406536101","volume":"101","author":"E Suzuki","year":"2004","unstructured":"Suzuki E, Handa K, Toledo MS, Hakomori S (2004) Sphingosine-dependent apoptosis: a unified concept based on multiple mechanisms operating in concert. Proc Natl Acad Sci USA 101:14788\u201314793","journal-title":"Proc Natl Acad Sci USA"},{"key":"882_CR51","doi-asserted-by":"crossref","first-page":"2600","DOI":"10.1158\/1535-7163.MCT-12-0605","volume":"11","author":"Y Shimura","year":"2012","unstructured":"Shimura Y, Kuroda J, Ri M et al (2012) RSK2Ser227 at N-terminal kinase domain is a potential therapeutic target for multiple myeloma. Mol Cancer Ther 11:2600\u20132609","journal-title":"Mol Cancer Ther"},{"key":"882_CR52","first-page":"5995","volume":"62","author":"C Ricci","year":"2002","unstructured":"Ricci C, Scappini B, Divoky V et al (2002) Mutation in the ATP-binding pocket of the ABL kinase domain in an STI571-resistant BCR\/ABL-positive cell line. Cancer Res 62:5995\u20135998","journal-title":"Cancer Res"},{"key":"882_CR53","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.critrevonc.2008.10.004","volume":"71","author":"J Kuroda","year":"2009","unstructured":"Kuroda J, Taniwaki M (2009) Involvement of BH3-only proteins in hematologic malignancies. Crit Rev Oncol Hematol 71:89\u2013101","journal-title":"Crit Rev Oncol Hematol"},{"key":"882_CR54","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.molcel.2005.02.003","volume":"17","author":"T Kuwana","year":"2005","unstructured":"Kuwana T, Bouchier-Hayes L, Chipuk JE et al (2005) BH3 domeins of BH3-only proteins differentially regulate Bax-mediated mitochondrial membrane permeabilization both directly and indirectly. Mol Cell 17:525\u2013535","journal-title":"Mol Cell"},{"key":"882_CR55","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1126\/science.1133289","volume":"315","author":"SN Willis","year":"2007","unstructured":"Willis SN, Fletcher JI, Kaufmann T et al (2007) Apopotosis initiated when BH3 ligands engage multiple Bcl-2 homologys, not Bax or Bak. Science 315:856\u2013859","journal-title":"Science"},{"key":"882_CR56","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1111\/j.1365-2141.2007.06899.x","volume":"140","author":"J Kuroda","year":"2008","unstructured":"Kuroda J, Kimura S, Andreeff M et al (2008) ABT-737 is a useful component of combinatory chemotherapies for chronic myeloid leukaemias with diverse drug-resistance mechanisms. Br J Haematol 140:181\u2013190","journal-title":"Br J Haematol"},{"key":"882_CR57","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1038\/leu.2010.67","volume":"24","author":"BA Burke","year":"2010","unstructured":"Burke BA, Carroll M (2010) BCR-ABL: a multi-faceted promoter of DNA mutation in chronic myelogeneous leukemia. Leukemia 24:1105\u20131112","journal-title":"Leukemia"},{"key":"882_CR58","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1016\/j.ejca.2009.04.005","volume":"45","author":"E San Jos\u00e9-Eneriz","year":"2009","unstructured":"San Jos\u00e9-Eneriz E, Agirre X, Jim\u00e9nez-Velasco A et al (2009) Epigenetic down-regulation of BIM expression is associated with reduced optimal responses to imatinib treatment in chronic myeloid leukaemia. Eur J Cancer 45:1877\u20131889","journal-title":"Eur J Cancer"},{"key":"882_CR59","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1158\/1541-7786.MCR-10-0040","volume":"8","author":"J Kuroda","year":"2010","unstructured":"Kuroda J, Yamamoto M, Nagoshi H et al (2010) Targeting activating transcription factor 3 by Galectin-9 induces apoptosis and overcomes various types of treatment resistance in chronic myelogenous leukemia. Mol Cancer Res 8:994\u20131001","journal-title":"Mol Cancer Res"},{"key":"882_CR60","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/j.yexcr.2012.03.005","volume":"318","author":"MH \u010cesen","year":"2012","unstructured":"\u010cesen MH, Pegan K, Spes A, Turk B (2012) Lysosomal pathways to cell death and their therapeutic applications. Exp Cell Res 318:1245\u20131251","journal-title":"Exp Cell Res"}],"container-title":["Apoptosis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10495-013-0882-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10495-013-0882-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10495-013-0882-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,14]],"date-time":"2024-05-14T15:13:17Z","timestamp":1715699597000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10495-013-0882-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,7,14]]},"references-count":60,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2013,11]]}},"alternative-id":["882"],"URL":"https:\/\/doi.org\/10.1007\/s10495-013-0882-y","relation":{},"ISSN":["1360-8185","1573-675X"],"issn-type":[{"value":"1360-8185","type":"print"},{"value":"1573-675X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,7,14]]}}}